Tinoco JC

Idioma: Español
Referencias bibliográficas: 20
Paginas: 52-57
Archivo PDF: 209.33 Kb.

FRAGMENTO

Las infecciones de las vías respiratorias inferiores, incluida la neumonía adquirida en la comunidad (NAC), se encuentran dentro de las 10 principales causas de mortalidad a nivel mundial. Fueron responsables de poco más de 3 millones de muertes en el mundo en el año 2012. Los individuos más frecuentemente afectados son los niños menores de 5 años y los adultos de ≥ 45 años, aunque la incidencia se incrementa de manera significativa en personas de ≥ 60 años.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Consultado el día 19 de Julio de 2015. Disponible en: http://www.who.int/mediacentre/factsheets/fs310/en/

2. Maggi S. Vaccination and healthy aging. Expert Rev Vaccines. 2010; (S3): 3-6.

3. Said MA, Johnson HL, Nonyane BA et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013; 8 (4): e60273.

4. Isturiz RE, Luna CM, Ramírez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010; 14: e852-856.

5. Sleeman KL, Daniels L, Gardiner M et al. Acquisition of Streptococcus pneumoniae and nonspecific morbidity in infants and their families: a cohort study. Pediatr Infect Dis J. 2005; 24: 121-127.

6. Geno KA, Gilbert GL, Song JY et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015; 28: 871-899.

7. Ludwig E, Bonanni P, Rohde G et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012; 21: 57-65.

8. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009; 9: 213-220.

9. Baltimore RS. New challenges in the development of a conjugate pneumococcal vaccine. JAMA. 1992; 268: 3366-3367.

10. Leventer-Roberts M, Feldman BS, Brufman I et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥ 65 years: a retrospective case-control study. Clin Infect Dis. 2015; 60: 1472-1480.

11. Moberley S, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; 1: CD000422.

12. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003; 348: 1737-1746.

13. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 20: 32-41.

14. Hsu HE, Shutt KA et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009; 360: 244-256.

15. Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis. 2012; 55: 259-264.

16. Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008; 66: 378-383.

17. Huijts SM, Pride MW, Vos JM et al. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J. 2013; 42: 1283-1290.

18. Tomczyk S, Bennett NM, Stoecker C et al. Use of 13-valent oneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged > 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63: 822-825.

19. Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R. The immunogenicity of Prevnar 13 in immunocompetent older adults with stable underlying medical conditions is comparable to that in healthy older adults. Presented at: IDWeek; October 17–21, 2012; San Diego, CA.

20. Schmoele-Thoma B, Jackson LA, Greenberg RN et al. The immunogenicity of PCV13 compared with PPSV23 in immunocompetent older adults with stable at-risk conditions. Presented at: IDWeek; October 8-12, 2014; Philadelphia, PA, USA.